1. Home
  2. ACRS vs CNNE Comparison

ACRS vs CNNE Comparison

Compare ACRS & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.71

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

CNNE

Cannae Holdings Inc.

HOLD

Current Price

$14.41

Market Cap

609.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
CNNE
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
608.9M
609.0M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
ACRS
CNNE
Price
$5.71
$14.41
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$10.20
$20.25
AVG Volume (30 Days)
2.0M
447.0K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
4.47%
EPS Growth
69.01
N/A
EPS
N/A
N/A
Revenue
$1,683,000.00
$499,700,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.37
52 Week Low
$1.46
$10.46
52 Week High
$5.76
$21.96

Technical Indicators

Market Signals
Indicator
ACRS
CNNE
Relative Strength Index (RSI) 71.95 53.69
Support Level $4.13 $13.83
Resistance Level N/A $15.03
Average True Range (ATR) 0.31 0.46
MACD 0.08 0.00
Stochastic Oscillator 92.26 71.75

Price Performance

Historical Comparison
ACRS
CNNE

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About CNNE Cannae Holdings Inc.

Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.

Share on Social Networks: